Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14771362 | 0.92 | MKNK1 (0.69) | MKNK1MKNK2 | |
| SCHEMBL14764108 | 0.92 | MKNK1 (0.69) | MKNK1MKNK2 | |
| SCHEMBL18901484 | 0.92 | MKNK1 (0.69) | MKNK1MKNK2 | |
| SCHEMBL15019844 | 0.88 | MKNK1 (0.60) | MKNK1MKNK2 | |
| SCHEMBL19316165 | 0.88 | MKNK1 (0.60) | MKNK1MKNK2 | |
| SCHEMBL16278330 | 0.88 | MKNK1 (0.60) | MKNK1MKNK2 | |
| SCHEMBL18901496 | 0.86 | MKNK1 (0.65) | MKNK1MKNK2 | |
| SCHEMBL14763738 | 0.86 | MKNK1 (0.65) | MKNK1MKNK2 | |
| SCHEMBL14763789 | 0.86 | MKNK1 (0.65) | MKNK1MKNK2 | |
| SCHEMBL14764101 | 0.85 | MKNK1 (0.69) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017157418-A1 | COMBINATION OF MKNK1-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | claimed |
| EP-2758401-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | claimed |
| US-9499547-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | claimed |
| US-20140296231-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | claimed |
| EP-2758401-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-07-30 | — | — | EP | claimed |
| WO-2013034570-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | WO | claimed |
| WO-2017157418-A1 | COMBINATION OF MKNK1-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| EP-2758401-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2758401-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-9499547-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-9499547-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-9499547-B2 | Amino-substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20140296231-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140296231-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140296231-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2758401-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013034570-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034570-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | CCNI, F12, MKI67 | MKNK1 2936/4885MKNK2 2926/4885 |
| US-20140296231-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, CCND2, CCND1 | MKNK1 2406/4885MKNK2 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.